These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37239206)

  • 1. Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders.
    Savino R; Polito AN; Marsala G; Ventriglio A; Di Salvatore M; De Stefano MI; Valenzano A; Marinaccio L; Bellomo A; Cibelli G; Monda M; Monda V; Messina A; Polito R; Carotenuto M; Messina G
    Brain Sci; 2023 Apr; 13(5):. PubMed ID: 37239206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
    Vimala PV; Bhutada PS; Patel FR
    Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease.
    Su Q; Li T; Liu GW; Zhang YL; Guo JH; Wang ZJ; Wu MN; Qi JS
    Neural Regen Res; 2023 Apr; 18(4):727-733. PubMed ID: 36204828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.
    Millan MJ
    Ther Adv Psychopharmacol; 2022; 12():20451253221105128. PubMed ID: 35795687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light.
    Tchekalarova J; Stoynova T; Ilieva K; Mitreva R; Atanasova M
    Pharmacol Biochem Behav; 2018 Aug; 171():1-9. PubMed ID: 29807067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agomelatine versus other antidepressive agents for major depression.
    Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008851. PubMed ID: 24343836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.
    Racagni G; Riva MA; Molteni R; Musazzi L; Calabrese F; Popoli M; Tardito D
    World J Biol Psychiatry; 2011 Dec; 12(8):574-87. PubMed ID: 21999473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks.
    Gahr M
    Curr Neuropharmacol; 2014 Sep; 12(5):287-398. PubMed ID: 25426008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine: An Astounding Sui-generis Antidepressant?
    Naveed M; Li LD; Sheng G; Du ZW; Zhou YP; Nan S; Zhu MY; Zhang J; Zhou QG
    Curr Mol Pharmacol; 2022; 15(7):943-961. PubMed ID: 34886787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
    Millan MJ; Gobert A; Lejeune F; Dekeyne A; Newman-Tancredi A; Pasteau V; Rivet JM; Cussac D
    J Pharmacol Exp Ther; 2003 Sep; 306(3):954-64. PubMed ID: 12750432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic mechanisms involved in the antidepressant effects of agomelatine.
    Tardito D; Molteni R; Popoli M; Racagni G
    Eur Neuropsychopharmacol; 2012; 22 Suppl 3():S482-6. PubMed ID: 22867907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.
    Kamal M; Gbahou F; Guillaume JL; Daulat AM; Benleulmi-Chaachoua A; Luka M; Chen P; Kalbasi Anaraki D; Baroncini M; Mannoury la Cour C; Millan MJ; Prevot V; Delagrange P; Jockers R
    J Biol Chem; 2015 May; 290(18):11537-46. PubMed ID: 25770211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian rhythms, melatonin and depression.
    Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
    Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction between the internal clock and antidepressant efficacy.
    Racagni G; Riva MA; Popoli M
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.
    Ettaoussi M; Sabaouni A; Pérès B; Landagaray E; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    ChemMedChem; 2013 Nov; 8(11):1830-45. PubMed ID: 24031039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of melatonin agonists.
    Cardinali DP; Pandi-Perumal SR; Srinivasan V; Spence DW; Trakht I
    Expert Rev Endocrinol Metab; 2008 Mar; 3(2):269-279. PubMed ID: 30764095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
    De Berardis D; Fornaro M; Serroni N; Campanella D; Rapini G; Olivieri L; Srinivasan V; Iasevoli F; Tomasetti C; De Bartolomeis A; Valchera A; Perna G; Mazza M; Di Nicola M; Martinotti G; Di Giannantonio M
    Int J Mol Sci; 2015 Jan; 16(1):1111-30. PubMed ID: 25569089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.